Abstract
Since the first successful cord blood transplant was performed in 1988 there has been a gradual increase in the use of cord blood for hemopoietic stem cell transplantation. Worldwide, over 8,000 unrelated cord blood transplants have been performed with the majority being for children with hemopoietic malignancies. Transplantation for adults has increased but is limited by the low number of nucleated cells and CD34+ cells within a single cord blood collection. Cord blood hemopoietic stem cells are more primitive than their adult counterparts and have high proliferative potential. Cord blood ex vivo expansion is designed to improve transplant outcomes by increasing the number of hemopoietic stem cells with long term repopulating potential and their differentiated progeny. However, despite a large amount of research activity during the last decade, this aim has not been realized. Herein we discuss the rationale for this approach; culture methods for ex vivo expansion, ways to assess the functional capacity of ex vivo generated hemopoietic stem cells and clinical outcomes following transplantation with ex vivo expanded cord blood.
Keywords: Stem cells, cord blood, ex vivo expansion, transplantation
Current Stem Cell Research & Therapy
Title: Expansion of Umbilical Cord Blood for Clinical Transplantation
Volume: 2 Issue: 4
Author(s): David N. Haylock and Susan K. Nilsson
Affiliation:
Keywords: Stem cells, cord blood, ex vivo expansion, transplantation
Abstract: Since the first successful cord blood transplant was performed in 1988 there has been a gradual increase in the use of cord blood for hemopoietic stem cell transplantation. Worldwide, over 8,000 unrelated cord blood transplants have been performed with the majority being for children with hemopoietic malignancies. Transplantation for adults has increased but is limited by the low number of nucleated cells and CD34+ cells within a single cord blood collection. Cord blood hemopoietic stem cells are more primitive than their adult counterparts and have high proliferative potential. Cord blood ex vivo expansion is designed to improve transplant outcomes by increasing the number of hemopoietic stem cells with long term repopulating potential and their differentiated progeny. However, despite a large amount of research activity during the last decade, this aim has not been realized. Herein we discuss the rationale for this approach; culture methods for ex vivo expansion, ways to assess the functional capacity of ex vivo generated hemopoietic stem cells and clinical outcomes following transplantation with ex vivo expanded cord blood.
Export Options
About this article
Cite this article as:
Haylock N. David and Nilsson K. Susan, Expansion of Umbilical Cord Blood for Clinical Transplantation, Current Stem Cell Research & Therapy 2007; 2 (4) . https://dx.doi.org/10.2174/157488807782793745
DOI https://dx.doi.org/10.2174/157488807782793745 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Systemic Treatment of Advanced Biliary Tract Carcinoma: Emerging Roles of Targeted Therapy and Molecular Profiling
Clinical Cancer Drugs Carcinogenesis and Therapeutic Strategies in Thyroid Cancer
Current Drug Targets Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Current Cancer Drug Targets Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
Current Pharmaceutical Design Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Etanercept for the Treatment of Dermatological Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Safety and Utilization of Blood Components as Therapeutic Delivery Systems
Current Pharmaceutical Biotechnology Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Imaging Studies in Hypercalcemia
Current Medicinal Chemistry The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Current Medicinal Chemistry